Valuation: Renalytix Plc

Market Cap 13.34M 11.7M 11.05M 10.07M 18.85M 1.28B 18.99M 132M 51.23M 653M 50.07M 48.99M 2.1B P/E 2024
-0.45x
P/E 2025 -1.34x
Enterprise Value 17.94M 15.74M 14.86M 13.55M 25.36M 1.72B 25.54M 178M 68.9M 878M 67.34M 65.89M 2.82B EV / Sales 2024
11,059,330x
EV / Sales 2025 12,499,418x
Free-Float
79.63%
Yield 2024 *
-
Yield 2025 -
1 day+50.38%
1 week+0.05%
Current month+0.05%
1 month+0.05%
3 months+82.55%
6 months+83.57%
Current year-14.91%
Current year 0.02
Extreme 0.0231
0.09
1 year 0.02
Extreme 0.0231
0.12
3 years 0.02
Extreme 0.0231
0.73
5 years 0.02
Extreme 0.0231
12.42
10 years 0.02
Extreme 0.0231
17.15
Manager TitleAgeSince
Chief Executive Officer 58 2018-03-14
Director of Finance/CFO 68 2024-05-27
President 65 2024-04-29
Director TitleAgeSince
Chairman 62 2024-11-04
Director/Board Member 58 2018-03-14
Chairman 74 -
Change 5-day change 1-year change 3-year change Capi.($)
+50.38%+0.05% - - 49.09M
-2.64%+4.03%+27.37%-18.75% 18.65B
-5.20%-1.26%-40.28%+23.38% 1.85B
0.00%-0.49%-32.73%+22.85% 866M
-0.11%-0.49%+50.49%-2.02% 778M
+2.34%-1.35%-59.01%-84.73% 733M
-0.69%+8.32%-30.46%-46.60% 686M
+1.77%+5.45%-38.77%-51.24% 589M
-0.69%+4.19%+51.32%+89.40% 476M
+5.05%+5.94%-0.46%+5.94% 399M
Average +5.14%+2.21%-8.06%-6.86% 2.78B
Weighted average by Cap. -1.86%+5.29%+15.35%-14.69%

Financials

2024 2025
Net sales 2.29 2.01 1.9 1.73 3.24 219.39 3.26 22.7 8.79 112.08 8.59 8.41 360.22 3 2.63 2.49 2.27 4.24 287.53 4.27 29.75 11.52 146.9 11.26 11.02 472.1
Net income -33.46M -29.36M -27.73M -25.27M -47.3M -3.21B -47.64M -332M -129M -1.64B -126M -123M -5.26B -20.4M -17.9M -16.91M -15.41M -28.84M -1.96B -29.05M -202M -78.36M -999M -76.59M -74.94M -3.21B
Net Debt 3.86M 3.38M 3.19M 2.91M 5.45M 369M 5.49M 38.23M 14.81M 189M 14.47M 14.16M 607M 4.6M 4.04M 3.81M 3.47M 6.5M 441M 6.55M 45.62M 17.67M 225M 17.27M 16.9M 724M
Logo Renalytix Plc
Renalytix plc is a United Kingdom-based company, which is engaged in the development of artificial intelligence-enabled clinical diagnostic solutions for kidney disease. The Company is engaged in a field of bioprognosis for kidney health. The Company has engineered a solution that enables early-stage chronic kidney disease progression risk assessment. KidneyIntelX, is a vitro diagnostic platform, employs a proprietary algorithm that combines diverse data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record or EHR, systems, to generate a patient risk score. KidneyIntelX has been granted designation by the United States Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.
Employees
46
Date Price Change Volume

Annual profits - Rate of surprise